ClinicalTrials.gg
CompletedNCT05030584OASIS-3Updated Dec 1, 2025Results posted

A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 52 Weeks in Women Who Have Been Through the Menopause

A Phase 3 interventional study of Elinzanetant (BAY3427080) and Placebo in Vasomotor Symptoms Associated With Menopause and Hot Flashes, sponsored by Bayer. Completed at 86 sites in 9 countries. Open to female participants aged 40 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-12-01.

Sponsored by Bayer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
628
Allocation
Randomized
Ages
40 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing elinzanetant in Hot Flashes — none open to participants now, 1 under way, 1 of them phase 3. elinzanetant · Hot Flashes.

Enrollment
Largest of 13
628 · median 64
Started
2021
with 4 others
Phase 3
4 of 13
none open now
Registered
4th of 13
by date
Lead sponsor
13 of 13
Bayer

Among the 13 studies testing elinzanetant in Hot Flashes, this one has the largest enrollment, is one of 5 that started in 2021, is one of 4 in phase 3, and was the 4th registered.

Hot Flashes

339 studies on the registry are indexed under Hot Flashes; 56 are open to participants now.

Browse Hot Flashes studies →

Open to participants now

None of the 13 studies testing elinzanetant in Hot Flashes is open now. The open studies under Hot Flashes, anywhere →

About elinzanetant

elinzanetant: first FDA approval 2025 (LYNKUET), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 36 Hot Flashes studies recruiting now, 13 (36%) set no upper age limit and 21 (58%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 40 Years to 65 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies testing elinzanetant in Hot Flashes as a file.
02

Study summary

Researchers are looking for a better way to treat women who have hot flashes after they have been through the menopause. Hot flashes are caused by the hormonal changes that happen when a woman's body has been through the menopause. Menopause is when women stop having a menstrual cycle, also called a period. During the menopause, the ovaries increasingly produce less sex hormones as a result of the natural ageing process and related hormonal adjustments. The decline in hormone production can lead to various symptoms which, in some cases, can have a very adverse effect on a menopausal woman's quality of life.

The study treatment, elinzanetant, was developed to treat symptoms caused by hormonal changes. It works by blocking a protein called neurokinin from sending signals to other parts of the body, which is thought to play a role in starting hot flashes. There are treatments for hot flashes in women who have been through the menopause, but may cause medical problems for some people.

In this study, the researchers will learn how well elinzanetant works compared to a placebo in women who have been through the menopause and have hot flashes. A placebo is a treatment that looks like a medicine but does not have any medicine in it. To compare these study treatments, the participants will record information about their hot flashes in an electronic diary. The researchers will study the number of hot flashes the participants have and how severe they are. They will study the results from before treatment and after 12 weeks of treatment.

The participants in this study will take two capsules of either elinzanetant or the placebo once a day. The participants will take the study treatments for 52 weeks.

During the study, the participants will visit their study site approximately 11 times and perform 2 visits by phone. Each participant will be in the study for approximately 62 weeks.

During the study, the participants will:

  • record information about their hot flashes in an electronic diary
  • answer questions about their symptoms

The doctors will:

  • check the participants' health
  • take blood samples
  • ask the participants questions about what medicines they are taking and if they are having adverse events An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments.
03

Conditions studied

  • Vasomotor Symptoms Associated With Menopause
  • Hot Flashes

Browse trials for

Keywords

  • Menopause
04

Who can participate

Ages eligible
40 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • , defined as:

    1. at least 12 months of spontaneous amenorrhea prior to signing of , or
    2. at least 6 months of spontaneous amenorrhea prior to signing of informed consent with serum follicle-stimulating hormone (FSH) levels > 40 mIU/mL and a serum estradiol concentration of \< 30 pg/mL, or
    3. at least 6 months after hysterectomy at signing of informed consent with serum FSH levels > 40 mIU/mL and a serum estradiol concentration of \< 30 pg/mL, or
    4. surgical bilateral oophorectomy with or without hysterectomy at least 6 weeks prior to signing of informed consent.
  • Moderate to severe hot flash (HF) associated with the menopause and seeking treatment for this condition.
  • Participant has completed Hot Flash Daily Diary (HFDD) for at least 11 days during the two weeks preceding baseline visit and is showing eligibility with respect to previous inclusion criterion during this time period.

Exclusion criteria

Exclusion Criteria:

  • Any prior or ongoing history of arrhythmias, heart block and either determined through clinical history or on evaluation.
  • Any active ongoing condition that could cause difficulty in interpreting vasomotor symptoms (VMS) such as: infection that could cause pyrexia, pheochromocytoma, carcinoid syndrome.
  • Current or history (except complete remission for 5 years or more) of any (except basal and squamous cell skin tumors). Women receiving endocrine therapy (e.g. tamoxifen, aromatase inhibitors, GnRH analogues) cannot be enrolled in this study.
  • Uncontrolled or treatment-resistant hypertension. Women with mild hypertension can be included in the study if they are medically cleared prior to study participation.
  • Untreated hyperthyroidism or hypothyroidism.

    • Treated hyperthyroidism with no abnormal increase of thyroid function laboratory parameters and no relevant clinical signs for > 6 months before signing of is acceptable.
    • Treated hypothyroidism with normal thyroid function test results during screening and a stable (for ≥ 3 months before signing of informed consent) dose of replacement therapy is acceptable.
  • Any unexplained uterine bleeding
  • Clinically relevant abnormal findings on mammogram.
  • Abnormal liver parameters.
  • Disordered proliferative endometrium, endometrial hyperplasia, polyp, or endometrial cancer diagnosed based on endometrial during screening.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
628 participants (actual)

Study arms

  • Experimental
    Elinzanetant (BAY3427080)

    Participants will receive 120 mg elinzanetant orally once daily.

    Drug: Elinzanetant (BAY3427080)

  • Placebo comparator
    Placebo

    Participants will receive matching placebo orally once daily.

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Change in Frequency of Moderate to Severe Hot Flashes (HFs) From Baseline to Week 12 (Assessed by Hot Flash Daily Diary [HFDD])

    The HFDD items assess the number of mild, moderate, and severe HF experienced during the day and during the night. Mild HF are defined as a "sensation of heat without sweating", moderate HF are defined as a "sensation of heat with sweating, but able to continue activity", and severe HF are defined as a "sensation of heat with sweating, causing cessation (stopping) of activity".

    Time frame: Baseline to Week 12

Secondary outcomes

  1. Mean Change in Patient-reported Outcomes Measurement Information System Sleep Disturbance Short Form 8b (PROMIS SD SF 8b) Total T-score From Baseline Over Time.

    The PROMIS SD SF 8b includes 8 items assessing sleep disturbance over the past 7 days. Items assess sleep quality, sleep depth and restoration associated with sleep, perceived difficulties with getting to sleep or staying asleep and perceptions of the adequacy of and satisfaction with sleep. Participants respond to the items on a 5-point scale from "not at all", "never" or "very poor" to "very much", "always" or "very good". Four of the items are scored reversely. Individual item scores are aggregated to total raw scores which range from 8 to 40. Total raw scores are converted into T-scores for comparison with population norms, with a mean of 50 and standard deviation of 10. T-scores range from 28.9 to 76.5. For both raw and T-scores higher scores indicate greater severity of sleep disturbance. According to available score cut points from PROMIS developers, T-scores can be interpreted as indicating mild (55-59), moderate (60-69), or severe (\>70) sleep disturbance.

    Time frame: Baseline to Week 56

  2. Mean Change in Menopause Specific Quality of Life Scale (MENQOL) Total Score From Baseline Over Time

    The MENQOL questionnaire is comprised of 29 items assessing the presence of menopausal symptoms and the impact of menopause on health-related quality of life over the past week. The items assess four domains of symptoms and functioning: Vasomotor functioning, psychosocial functioning, physical functioning, and sexual functioning. For each item, the participant indicates if they have experienced the symptom (yes/no). If they select yes, they rate how bothered they were by the symptom using a six-point verbal descriptor scale, with response options ranging from 0 'not at all bothered' to 6 'extremely bothered'. Based on the individual responses, item scores, domain scores, and a total MENQOL score are calculated. Each score ranges from 1-8, higher scores indicate greater bother.

    Time frame: Baseline to Week 56

07

Results

Posted Dec 1, 2025

Participant flow

The study was conducted at 75 study centers in North America and in several countries in Europe, between 27-Aug-2021 (first participant first visit) and 12-Feb-2024 (last participant last visit).

Participant flow — Overall Study
MilestoneElinzanetant (BAY3427080)Placebo
Started313315
Received treatment312315
Completed222231
Not completed9184
Withdrew: Adverse event172
Withdrew: Lack of efficacy06
Withdrew: Lost to follow-up52
Withdrew: Non-compliance with study drug23
Withdrew: Other reason43
Withdrew: Physician decision14
Withdrew: Protocol violation02
Withdrew: Randomized by mistake02
Withdrew: Withdrawal by subject2128
Withdrew: Technical problems01
Withdrew: Completed post-treatment/fu visits4131

Outcome measures

PrimaryMean Change in Frequency of Moderate to Severe Hot Flashes (HFs) From Baseline to Week 12 (Assessed by Hot Flash Daily Diary [HFDD])

The HFDD items assess the number of mild, moderate, and severe HF experienced during the day and during the night. Mild HF are defined as a "sensation of heat without sweating", moderate HF are defined as a "sensation of heat with sweating, but able to continue activity", and severe HF are defined as a "sensation of heat with sweating, causing cessation (stopping) of activity".

Time frame:
Baseline to Week 12
Reported as:
Mean · Number of HF
Mean Change in Frequency of Moderate to Severe Hot Flashes (HFs) From Baseline to Week 12 (Assessed by Hot Flash Daily Diary [HFDD])
Number of HFElinzanetant (BAY3427080)Placebo
Baseline6.71 ± 7.156.81 ± 6.15
Change from Baseline-5.40 ± 7.29-3.50 ± 4.96
Statistical analysis
  • Elinzanetant (BAY3427080) vs Placebo · Mixed model repeated measures (MMRM) · p = <0.0001 (The type I error rate was controlled at a one-sided α=0.025 level.) · Difference in ls-means: -1.55 · 95% CI -2.04 to -1.05
SecondaryMean Change in Patient-reported Outcomes Measurement Information System Sleep Disturbance Short Form 8b (PROMIS SD SF 8b) Total T-score From Baseline Over Time.

The PROMIS SD SF 8b includes 8 items assessing sleep disturbance over the past 7 days. Items assess sleep quality, sleep depth and restoration associated with sleep, perceived difficulties with getting to sleep or staying asleep and perceptions of the adequacy of and satisfaction with sleep. Participants respond to the items on a 5-point scale from "not at all", "never" or "very poor" to "very much", "always" or "very good". Four of the items are scored reversely. Individual item scores are aggregated to total raw scores which range from 8 to 40. Total raw scores are converted into T-scores for comparison with population norms, with a mean of 50 and standard deviation of 10. T-scores range from 28.9 to 76.5. For both raw and T-scores higher scores indicate greater severity of sleep disturbance. According to available score cut points from PROMIS developers, T-scores can be interpreted as indicating mild (55-59), moderate (60-69), or severe (\>70) sleep disturbance.

Time frame:
Baseline to Week 56
Reported as:
Mean · T-score
Mean Change in Patient-reported Outcomes Measurement Information System Sleep Disturbance Short Form 8b (PROMIS SD SF 8b) Total T-score From Baseline Over Time.
T-scoreElinzanetant (BAY3427080)Placebo
Baseline57.35 ± 6.6657.96 ± 7.63
Change from baseline to Week 1-5.19 ± 7.17-1.60 ± 5.39
Change from baseline to Week 2-6.78 ± 7.96-2.89 ± 6.78
Change from baseline to Week 3-7.67 ± 8.24-3.34 ± 6.88
Change from baseline to Week 4-7.70 ± 8.27-3.81 ± 6.98
Change from baseline to Week 8-7.98 ± 8.58-4.36 ± 7.64
Change from baseline to Week 12-7.97 ± 8.04-5.26 ± 8.02
Change from baseline to Week 18-8.83 ± 9.05-5.77 ± 7.82
Change from baseline to Week 24-9.77 ± 9.00-5.85 ± 7.79
Change from baseline to Week 36-9.20 ± 8.74-5.88 ± 8.38
Change from baseline to Week 52-9.36 ± 8.41-5.73 ± 7.91
Change from baseline to Week 56 (Follow-up)-5.83 ± 8.71-5.38 ± 7.50
SecondaryMean Change in Menopause Specific Quality of Life Scale (MENQOL) Total Score From Baseline Over Time

The MENQOL questionnaire is comprised of 29 items assessing the presence of menopausal symptoms and the impact of menopause on health-related quality of life over the past week. The items assess four domains of symptoms and functioning: Vasomotor functioning, psychosocial functioning, physical functioning, and sexual functioning. For each item, the participant indicates if they have experienced the symptom (yes/no). If they select yes, they rate how bothered they were by the symptom using a six-point verbal descriptor scale, with response options ranging from 0 'not at all bothered' to 6 'extremely bothered'. Based on the individual responses, item scores, domain scores, and a total MENQOL score are calculated. Each score ranges from 1-8, higher scores indicate greater bother.

Time frame:
Baseline to Week 56
Reported as:
Mean · Scores on a scale
Mean Change in Menopause Specific Quality of Life Scale (MENQOL) Total Score From Baseline Over Time
Scores on a scaleElinzanetant (BAY3427080)Placebo
Baseline4.10 ± 1.214.41 ± 1.37
Change from baseline to Week 4-0.94 ± 1.22-0.67 ± 1.21
Change from baseline to Week 8-1.07 ± 1.24-0.86 ± 1.18
Change from baseline to Week 12-1.10 ± 1.25-0.95 ± 1.32
Change from baseline to Week 18-1.30 ± 1.32-1.11 ± 1.40
Change from baseline to Week 24-1.25 ± 1.17-1.15 ± 1.37
Change from baseline to Week 36-1.18 ± 1.21-1.02 ± 1.42
Change from baseline to Week 52-1.30 ± 1.33-1.11 ± 1.35
Change from baseline to Week 56 (Follow-up)-0.82 ± 1.25-1.04 ± 1.59

Adverse events

Collected over Adverse events tables: up to 14 days from the last drug intake, up to 54 weeks. All-cause mortality table: after signing informed consent up to the last contact per participant, up to 62 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Elinzanetant (BAY3427080)0/313 (0%)13/313 (4.2%)85/313 (27.2%)
Placebo0/314 (0%)6/314 (1.9%)73/314 (23.2%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventElinzanetant (BAY3427080)Placebo
Acute myocardial infarctionCardiac disorders1/3130/314
VertigoEar and labyrinth disorders1/3130/314
EpiglottitisInfections and infestations1/3130/314
Fusobacterium infectionInfections and infestations1/3130/314
Meningitis meningococcalInfections and infestations1/3130/314
ConcussionInjury, poisoning and procedural complications1/3130/314
InjuryInjury, poisoning and procedural complications1/3130/314
Blood glucose increasedInvestigations1/3130/314
OsteoarthritisMusculoskeletal and connective tissue disorders1/3131/314
Rotator cuff syndromeMusculoskeletal and connective tissue disorders1/3130/314
Most frequent other events
Most frequent other events
EventElinzanetant (BAY3427080)Placebo
COVID-19Infections and infestations22/31332/314
HeadacheNervous system disorders30/31322/314
FatigueGeneral disorders21/3139/314
NasopharyngitisInfections and infestations15/31321/314
SomnolenceNervous system disorders16/3134/314

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Elinzanetant (BAY3427080)PlaceboTotal
Mean54.6 ± 4.754.9 ± 5.054.7 ± 4.8
Sex: Female, Male
Sex: Female, Male(Participants)Elinzanetant (BAY3427080)PlaceboTotal
Female313315628
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Elinzanetant (BAY3427080)PlaceboTotal
Hispanic or Latino343468
Not Hispanic or Latino266273539
Unknown or Not Reported13821
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Elinzanetant (BAY3427080)PlaceboTotal
American Indian or Alaska Native000
Asian224
Native Hawaiian or Other Pacific Islander101
Black or African American514495
White240253493
More than one race011
Unknown or Not Reported191534
08

Study locations

86 sites
  • Mobile ObGyn, P.C. | Mobile, AL
    Mobile, Alabama 36608, United States
  • Mesa Obstetricians and Gynecologists | Research Department
    Mesa, Arizona 85206, United States
  • National Institute of Clinical Research - Garden Grove
    Garden Grove, California 92844, United States
  • Marvel Clinical Research | Huntington Beach, CA
    Huntington Beach, California 92647, United States
  • Empire Clinical Research | Pomona, CA
    Pomona, California 91767, United States
  • Coastal Connecticut Research | New London, CT
    New London, Connecticut 06320, United States
  • IntimMedicine | Washington, DC
    Washington D.C., District of Columbia 20036, United States
  • Boca Midwifery
    Boca Raton, Florida 33486, United States
  • Helix Biomedics LLC | Boynton Beach, FL
    Boynton Beach, Florida 33435, United States
  • UF Health Women's Specialists - Emerson
    Jacksonville, Florida 32207, United States
  • Suncoast Clinical Research - Palm Harbor
    Palm Harbor, Florida 34684, United States
  • Physician Care Clinical Research LLC | Sarasota, FL
    Sarasota, Florida 34239, United States
  • Suncoast Clinical Research - New Port Richey
    Trinity, Florida 34655, United States
  • Paramount Research Solutions | College Park Location
    College Park, Georgia 30349, United States
  • Investigators Research Group, LLC
    Brownsburg, Indiana 46112, United States
  • Southern Clinical Research Associates
    Metairie, Louisiana 70001, United States
  • Southern Clinical Research, LLC
    Zachary, Louisiana 70791, United States
  • Johns Hopkins Hospital - Gynecology and Obstetrics
    Baltimore, Maryland 21287, United States
  • Boeson Research | Great Falls, MT
    Great Falls, Montana 59405, United States
  • Boeson Research | Missoula, MT
    Missoula, Montana 59804, United States
  • Affiliated Clinical Research, Inc. | Las Vegas, NV
    Las Vegas, Nevada 89113, United States
  • AMR - Las Vegas
    Las Vegas, Nevada 89119, United States
  • Elite Clinical Network (ECN) | Las Vegas Clinical Trials, LLC
    North Las Vegas, Nevada 89030, United States
  • M3 Wake Research | Raleigh, NC
    Raleigh, North Carolina 27612, United States
  • ClinOhio Research Services, LLC. | Columbus, OH
    Columbus, Ohio 43213, United States
  • HWC Women's Research Center | Englewood, OH
    Englewood, Ohio 45322, United States
  • Clinical Research Philadelphia | Philadelphia, PA
    Philadelphia, Pennsylvania 19114, United States
  • Venus Gynecology, LLC | Myrtle Beach, SC
    Myrtle Beach, South Carolina 29572, United States
  • Advances in Health, INC. | Houston, TX
    Houston, Texas 77030, United States
  • UTHealth Womens Research Program | Memorial City
    Houston, Texas 77054, United States
  • Elligo Health Research | Medical Colleagues of Texas
    Hurst, Texas 76054, United States
  • Elligo Health Research | Protenium Clinical Research
    Katy, Texas 77493, United States
  • Maximos Ob/Gyn
    League City, Texas 77573, United States
  • Tidewater Clinical Research - Norfolk
    Norfolk, Virginia 23502, United States
  • Eastern Virginia Medical School | OB/GYN Clinical Research Center
    Norfolk, Virginia 23507, United States
  • Seattle Clinical Research Center
    Seattle, Washington 98105, United States
  • CHU Saint-Pierre/UMC Sint-Pieter
    Bruxelles - Brussel, 1000, Belgium
  • UZ Gent
    Ghent, 9000, Belgium
  • UZ Leuven Gasthuisberg
    Leuven, 3000, Belgium
  • CHU de Liege | CHR Citadel - Department of Gyneacology and Obstetrics
    Liège, 4000, Belgium
  • Femicare vzw | Tienen, BE
    Tienen, 3300, Belgium
  • Medical Centre Asklepii OOD | Dupnitsa, Bulgaria
    Dupnitsa, 2600, Bulgaria
  • Multiprofile Hospital for Active Treatment | Avis Medica - Obstetrics and Gynecology
    Pleven, 5800, Bulgaria
  • Multiprofile Hospital for Active Treatment Plovdiv | Obstetrics and Gynecology
    Plovdiv, 4000, Bulgaria
  • Spec.Hospital for obstetrics and gynecology Selena OOD
    Plovdiv, 4002, Bulgaria
  • Multiprofile Hospital for Active Treatment Samokov | Gynecology Department
    Samokov, 2000, Bulgaria
  • Specialized Hospital for Active Treatment of Oncological Diseases Sofia Region | Oncological Gynecology Department
    Sofia, 1233, Bulgaria
  • Multiprofile Hospital for Active Treatment for Women's Health Nadezhda | Department of Obstetrics and Gynecology
    Sofia, 1330, Bulgaria
  • Diagnostic-Consultative Center Alexandrovska | Sofia, Bulgaria
    Sofia, 1431, Bulgaria
  • Medical Center Panacea OOD | Sofia, Bulgaria
    Sofia, 1606, Bulgaria
  • Multiprofile Hospital for Active Treatment Niamed OOD | Department of Obstetrics and Gynecology
    Stara Zagora, 6000, Bulgaria
  • SBAGAL Dr. Dimitar Stamatov | Varna, Bulgaria
    Varna, 9000, Bulgaria
  • IWK Health Centre | Department of Obstetrics and Gynaecology
    Halifax, Nova Scotia B3K 6R8, Canada
  • Manna Research (Burlington North)
    Burlington, Ontario L7M 4Y1, Canada
  • Manna Research (Ottawa)
    Nepean, Ontario K2J 4A7, Canada
  • Ottawa Hospital-Riverside Campus
    Ottawa, Ontario K1H 7W9, Canada
  • Viable Clinical Research | Mississauga, Canada
    Scarborough Village, Ontario M1P 2T7, Canada
  • Manna Research (Quebec)
    Lévis, Quebec G6W 0M5, Canada
  • Manna Research (Montreal)
    Pointe-Claire, Quebec H9R 4S3, Canada
  • Alpha Recherche Clinique | Lebourgneuf
    Québec, G2J 0C4, Canada
  • Sanos Clinic | Gandrup, Denmark
    Gandrup, 9362, Denmark
  • Sanos Clinic | Herlev, Denmark
    Herlev, 2730, Denmark
  • Sanos Clinic | Syddanmark, Vejle, Denmark
    Vejle, 7100, Denmark
  • HUS / Naistenklinikka
    Helsinki, 29, Finland
  • Pihlajalinna Lääkärikeskus Oy, Savo-Karjala
    Joensuu, 80100, Finland
  • Mehilainen | Mehilainen Kuopio
    Kuopio, 70100, Finland
  • Lääkärikeskus Gyneko, Gynaecological Medical Center | Oulu, Finland
    Oulu, 90100, Finland
  • Terveystalo | Terveystalo Tampere Research Unit
    Tampere, 33100, Finland
  • Gabinet Ginekologiczny Janusz Tomaszewski
    Bialystok, 15-224, Poland
  • CLINICAL MEDICAL RESEARCH Sp. z o. o.
    Katowice, 40-156, Poland
  • Centrum Medyczne Angelius Provita
    Katowice, 40-611, Poland
  • Vita Longa Sp. z o.o.
    Katowice, 40-748, Poland
  • Twoja Przychodnia - Szczecinskie Centrum Medyczne
    Szczecin, 71-500, Poland
  • Centrum Badawcze Wspolczesnej Terapii
    Warsaw, 02-679, Poland
  • Hospital Universitario La Zarzuela - Ginecologia
    Aravaca, Madrid 28023, Spain
  • Hospital de la Santa Creu i Sant Pau | Gynecology Department
    Barcelona, 8041, Spain
  • Instituto Palacios | Investigation Research Unit - Gynecology department
    Madrid, 28009, Spain
  • Hospital Clinico San Carlos | Women´s Health Institute
    Madrid, 28040, Spain
  • Hospital Universitario 12 de Octubre | Department of Obstetrics and Gynecology
    Madrid, 28041, Spain
  • Virgen del Rocio University Hospital | Gynecology Unit
    Seville, 41013, Spain
  • Hospital Clinico Universitario | Gynecology and Obstetrics Department
    Valencia, 46010, Spain
  • MAC Clinical Research | Lancashire - Clinical Research Centre
    Blackpool, FY2 0JH, United Kingdom
  • NHS Greater Glasgow and Clyde | Glasgow Royal Infirmary - Gynaecology
    Glasgow, G4 0SF, United Kingdom
  • Liverpool Women's NHS Foundation Trust | Liverpool Women's Hospital - Gynaecology
    Liverpool, L8 7SS, United Kingdom
  • Imperial College Healthcare NHS Trust| Queen Charlotte's and Chelsea Hospital - Gynaecology
    London, W12 0NN, United Kingdom
  • MAC Clinical Research | Greater Manchester Early Phase - Clinical Research Centre
    Manchester, M13 9NQ, United Kingdom
09

References and documents

Publications

  • Panay N, Joffe H, Maki PM, Nappi RE, Pinkerton JV, Simon JA, Soares CN, Thurston RC, Francuski M, Caetano C, Genga K, Haberland C, Haseli Mashhadi N, Laapas K, Parke S, Seitz C, Schwarz J, Zuurman L. Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause: A Phase 3 Randomized Clinical Trial. JAMA Intern Med. 2025 Nov 1;185(11):1319-1327. doi: 10.1001/jamainternmed.2025.4421. PubMed 40920404 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2021 to primary completion in Mar 2023, 19 months.

Results were first posted in Dec 2025, 2 years 8 months after primary completion. A results delay was requested in Mar 2024.

Of 23 phase 3 interventional studies under Hot Flashes, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 29. This study's 19 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2021
First posted
Sep 1, 2021
StartActual
Aug 27, 2021
Primary completionActual
Mar 29, 2023
CompletionActual
Feb 12, 2024
Results delay requested
Mar 13, 2024
Results first posted
Dec 1, 2025
Last update
Dec 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05030584
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Sep 1, 2021
Start date
Aug 27, 2021
Primary completion
Mar 29, 2023
Completion
Feb 12, 2024
Results posted
Dec 1, 2025
Last update
Dec 1, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elinzanetant

Start the discussion